You need IP intelligence to meet corporate objectives related to your business function. IP Street is driving the innovation economy and managing IP assets with know-how and confidence. IP Street.com takes a patent search to a whole new level by helping you better understand patent analytics, patent duration, patent value, patent infringement and the steps needed to patent an idea or patent an invention.

In your written patent application you must fully describe your invention to such a degree that a person skilled in the same field as the invention could make or use that invention. A person skilled in the same field as the invention should be able to read your patent application and understand it. The inventor must be able to make claims about his/her invention in clear and definite terms.The part of a patent application that describes and reveals your invention is called the specification and includes various types of descriptions, claims, and drawings depending on the type of invention and type of patent involved. Remember, ideas alone cannot be patented. In other words - you can't just write, "I have an idea for a new alarm clock." You must be able to describe how your alarm works so that an expert in alarm clocks would understand how it would work and that it would indeed work. It's like a recipe ... a good cook should be able to produce your invention based on your patent. As a novice, to file your first patent application yourself is often unwise. However, you could write your own descriptions and then pass them over to your attorney. The attorney could use your writings as a guide and a time-saver, and that will save you money. You should present your inventor's logbook, prototype, and any prior art searches to the attorney. You must write a complete and thorough description of your intellectual property as you cannot add any new information to your patent application once it is filed. You can only make changes to the subject matter that could be reasonably inferred from the original drawings or description.

Asexual reproduction is the propagation of a plant to multiply the plant without the use of genetic seeds to assure an exact genetic copy of the plant being reproduced. Any known method of asexual reproduction which renders a true genetic copy of the plant may be employed. Acceptable modes of asexual reproduction would include but may not be limited to: (1) rooting cuttings (2) apomictic seeds (3) grafting and budding (4) division (5) layering (6) bulbs (7) slips (8) rhizomes (9) corms (10) runners (11) tissue culture (12)nucellar embryos

Lee is IP Street's CEO. Art Coffey, a business strategist who took RLH public on the NYSE as its CFO, best known for his leadership as the President and Chief Executive Officer of Red Lion Hotels Corporation from 2003 to 2008, is COO & CFO. Tammy Krieger, Director of Product Management, was formerly in a leading role with Microsoft's patent group and brings expertise in data management, patent analysis and process optimization. John Vogel, Vice President of Engineering, leads the software development team, formerly co-founded and developed Saas companies such as Four Creeks. The team is backed by a board of directors that include Stacey Cowles (Cowles Company), Dennis Hopton (York Trade Limited of Hong Kong), George Nethercutt (former U.S. Representative), and Lee and Coffey. IP Street's advisory board includes Roger Cheng (Alibaba), Scott Hayden (Amazon), Shawn Clark (Microsoft), Dan Crouse (Lee & Hayes), John Murphy (T-Mobile), and Joseph Schappert, MD (PAML). The company is privately funded.

Myopia is generally what happens when unprecedented opportunities are placed before them. Those in the know generally do better than those in the worry. Consider Cetus, a startup biotech with a focus on a liver drug. The FDA delayed the approval of the drug, and a major funding crisis ensued. Chiron offered to take over the liabilities contingent on the sale of two patents (# 4,683,202 and # 4,683,195) to a third party, Roche Molecule for $300M (in 1993). This sale was stalled because DuPont challenged the validity of the patents, based on the formal claims written by the inventor (not a patent attorney), Kary Mullis. In the end, the soap opera turned out well for the investors with weak constitutions. For $300M, they sold the two patents to Roche, turned the company over to Chiron, and walked away. Kary Mullis won the Nobel prize for his invention embedded in these two patents, known as polymerase chain reaction (PCR) which allows DNA to be cloned. Over 4000 patents in biotech cite these original two patents. In our estimation, $300M represents "pennies on the dollar" valuation of these patents. The shareholders got a payday, and left the game. Roche on the other hand is thriving based on its intangible assets. Let IPstreet.com assist you.